Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 ISIN · KYG1821D1097 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2023-02-03 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 January 2023. It details movements in authorized and issued share capital, share options, and other share-related information. It is submitted to the Hong Kong Exchanges and Clearing Limited and includes confirmations and notes related to share capital movements. The document is a regulatory submission about share capital and share movements rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings data but focuses on share capital changes and share option schemes. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes. The document length (7164 characters) and detailed share capital data support this classification with high confidence.
2023-02-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in authorized and issued share capital, share options, and other share-related movements for CANbridge Pharmaceuticals Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and relates to the month ended 31 December 2022. The content includes tables of share capital balances, share option schemes, and confirmations related to securities movements. There is no indication of financial statements, earnings data, management discussion, or audit information. The document is regulatory in nature, reporting share capital changes and share issuance activities, which aligns with announcements regarding share issues or capital changes. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive regulatory filing on share capital movements.
2023-01-05 English
VOLUNTARY ANNOUNCEMENT UPDATE ON COLLABORATIONS WITH THE UMASS CHAN MEDICAL SCHOOL AND WITH LOGICBIO THERAPEUTICS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CANbridge Pharmaceuticals Inc. providing updates on business collaborations and technology transfers related to gene therapy programs. It includes detailed information about the company's agreements, rights secured, and ongoing research developments. The document is not a full financial report, audit, earnings release, or regulatory filing. It is a business update announcement focusing on collaborations and strategic developments rather than financial results or governance changes. The length (over 11,000 characters) and content indicate it is more than a brief fact sheet or simple announcement. It does not fit categories like M&A filings, director dealings, or dividend notices. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories such as capital updates, earnings, or management reports.
2023-01-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2022
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 November 2022. It details movements in authorized and issued shares, share options, and other share-related information for CANbridge Pharmaceuticals Inc. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited. The document is a periodic regulatory filing reporting share capital and share movements, not a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary. It is not an announcement of a report publication but the actual regulatory return. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-05 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Capital/Financing Update Classification · 95% confidence The document is an announcement from CANbridge Pharmaceuticals Inc. regarding the grant of share options and restricted share units (RSUs) to employees and directors. It details the number of options and RSUs granted, the vesting schedules, exercise prices, and related approvals by the board and independent directors. The content focuses on share-based compensation and equity incentive plans, which is a capital structure and financing activity. There is no financial statement or comprehensive financial report included, nor is it a regulatory certification or voting result announcement. The document is not an annual or interim report, earnings release, or management discussion. It is a formal announcement about share option and RSU grants, which fits best under Capital/Financing Update (CAP). The document length is 8844 characters, which is substantive and contains detailed information about the grants, not just a brief notice or report publication announcement.
2022-11-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued share capital, share options, and other share-related movements for CANbridge Pharmaceuticals Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules under Chapter 19B. The content includes detailed tables of share capital changes, share options, and confirmations related to share issuance and movements. There is no indication that this is an announcement of a report or a brief summary; rather, it is a regulatory filing providing detailed share capital information for a specific month (October 2022). This type of document aligns with a Major Shareholding Notification or Share Issue/Capital Change. Since it details movements in issued shares and share capital without indicating a new share issue or capital change event like a stock split or new issuance, but rather movements and confirmations, the best fit is Share Issue/Capital Change (SHA).
2022-11-03 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.